Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTICCA-1: Adjuvant Gem/Cis vs Capecitabine in Biliary Tract Cancer
NCT02170090Phase 3Active, not recruiting
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Apr 2014
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of gemcitabine, cisplatin in cholangiocarcinoma (CCA), gallbladder carcinoma, sponsored by University Medical Center Hamburg-Eppendorf. Started Apr 2014; status: active, not recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
cholangiocarcinoma (CCA)gallbladder carcinoma
Beyond the preview
Go deeper on NCT02170090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170090.